These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 36036858

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Clinical and Immunological Impact of Ocrelizumab Extended Interval Dosing in Multiple Sclerosis: A Single-Center, Real-World Experience.
    Nasello M, Zancan V, Rinaldi V, Marrone A, Reniè R, Diamant S, Marconi M, Le Mura L, Salvetti M, Buscarinu MC, Bellucci G.
    Int J Mol Sci; 2024 May 14; 25(10):. PubMed ID: 38791391
    [Abstract] [Full Text] [Related]

  • 3. Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19.
    Rolfes L, Pawlitzki M, Pfeuffer S, Nelke C, Lux A, Pul R, Kleinschnitz C, Kleinschnitz K, Rogall R, Pape K, Bittner S, Zipp F, Warnke C, Goereci Y, Schroeter M, Ingwersen J, Aktas O, Klotz L, Ruck T, Wiendl H, Meuth SG.
    Neurol Neuroimmunol Neuroinflamm; 2021 Sep 14; 8(5):. PubMed ID: 34261812
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience.
    Zanghì A, Ferraro D, Callari G, Valentino P, Granella F, Patti F, Lus G, Bonavita S, Moretti MC, Avolio C, D'Amico E.
    Curr Neuropharmacol; 2024 Sep 14; 22(2):339-345. PubMed ID: 37876043
    [Abstract] [Full Text] [Related]

  • 6. COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients.
    Bisecco A, Matrone F, Capobianco M, De Luca G, Filippi M, Granella F, Lus G, Marfia GA, Mirabella M, Patti F, Trojano M, Mascolo A, Copetti M, Tedeschi G, Gallo A, OCREVID study group on behalf of the Italian MS Register.
    J Neurol; 2024 Feb 14; 271(2):699-710. PubMed ID: 37982852
    [Abstract] [Full Text] [Related]

  • 7. No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS.
    Ryerson LZ, Naismith RT, Krupp LB, Charvet LE, Liao S, Fisher E, de Moor C, Williams JR, Campbell N.
    Mult Scler Relat Disord; 2022 Feb 14; 58():103480. PubMed ID: 35051898
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Extended interval dosing with ocrelizumab in multiple sclerosis.
    Novak F, Bajwa HM, Østergaard K, Berg JM, Madsen JS, Olsen DA, Urbonaviciute I, Illes Z, Stilund ML, Romme Christensen J, Bramow S, Sellebjerg F, Sejbaek T.
    Mult Scler; 2024 Jun 14; 30(7):847-856. PubMed ID: 38646949
    [Abstract] [Full Text] [Related]

  • 11. Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis.
    Rodriguez-Mogeda C, van Lierop ZYGJ, van der Pol SMA, Coenen L, Hogenboom L, Kamermans A, Rodriguez E, van Horssen J, van Kempen ZLE, Uitdehaag BMJ, Teunissen CE, Witte ME, Killestein J, de Vries HE.
    J Neuroinflammation; 2023 Sep 26; 20(1):215. PubMed ID: 37752582
    [Abstract] [Full Text] [Related]

  • 12. sNFL applicability as additional monitoring tool in natalizumab extended interval dosing regimen for RRMS patients.
    Valentino P, Malucchi S, Martire S, Bava CI, Capobianco MA, Bertolotto A.
    Mult Scler Relat Disord; 2022 Nov 26; 67():104176. PubMed ID: 36126541
    [Abstract] [Full Text] [Related]

  • 13. Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study.
    Manchon E, Laplaud D, Vukusic S, Labauge P, Moreau T, Kobelt G, Grouin JM, Lotz M, Pau D, Christine LF.
    Mult Scler Relat Disord; 2022 Dec 26; 68():104109. PubMed ID: 36007299
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Ocrelizumab B-cell repopulation-guided extended interval dosing versus standard dosing - similar clinical efficacy with decreased immunoglobulin M deficiency rates.
    Rempe T, Elfasi A, Rodriguez E, Vasquez M, Graves J, Kinkel R.
    Mult Scler Relat Disord; 2023 Nov 26; 79():105028. PubMed ID: 37813071
    [Abstract] [Full Text] [Related]

  • 16. MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study.
    De Mercanti SF, Signori A, Cordioli C, Signoriello E, Lus G, Bonavita S, Abbadessa G, Lavorgna L, Maniscalco GT, Curti E, Lorefice L, Cocco E, Nociti V, Mirabella M, Baroncini D, Mataluni G, Landi D, Petruzzo M, Lanzillo R, Gandoglia I, Laroni A, Frangiamore R, Sartori A, Cavalla P, Costantini G, Capra R, Sormani MP, Clerico M.
    J Neurol Sci; 2021 May 15; 424():117385. PubMed ID: 33770708
    [Abstract] [Full Text] [Related]

  • 17. Natalizumab extended interval dosing: what about wearing-off effect?
    Bernardes C, Fernandes C, Cunha C, Nunes C, Macário C, Sousa L, Batista S, Correia I.
    J Neurol Sci; 2024 Mar 15; 458():122930. PubMed ID: 38368641
    [Abstract] [Full Text] [Related]

  • 18. Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.
    Mancinelli CR, Scarpazza C, Cordioli C, De Rossi N, Rasia S, Turrini MV, Capra R.
    Mult Scler; 2021 Apr 15; 27(5):790-794. PubMed ID: 32749910
    [Abstract] [Full Text] [Related]

  • 19. Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness.
    Barun B, Gabelić T, Adamec I, Babić A, Lalić H, Batinić D, Krbot Skorić M, Habek M.
    Mult Scler Relat Disord; 2021 Feb 15; 48():102704. PubMed ID: 33370649
    [Abstract] [Full Text] [Related]

  • 20. Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).
    Toorop AA, van Lierop ZY, Gelissen LM, Hoitsma E, Zeinstra EM, van Rooij LC, van Munster CE, Vennegoor A, Mostert JP, Wokke BH, Kalkers NF, Hoogervorst EL, van Eijk JJ, Roosendaal CM, Kragt JJ, Eurelings M, van Genugten J, Nielsen J, Sinnige L, Kloosterziel ME, Arnoldus EP, van Dijk GW, Bouvy WH, Wessels MH, Boonkamp L, Strijbis EM, van Oosten BW, De Jong BA, Lissenberg-Witte BI, Barkhof F, Moraal B, Teunissen CE, Rispens T, Uitdehaag BM, Killestein J, van Kempen ZL.
    J Neurol Neurosurg Psychiatry; 2024 Apr 12; 95(5):392-400. PubMed ID: 37963723
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.